Charles Provine is an associate in the Intellectual Property Litigation Group based in Morrison Foerster's Boston office. Charles’ practice focuses on patent and trade secret litigation, with an emphasis on counseling life sciences and technology companies in high-stakes patent disputes. He has experience working with clients in the pharmaceutical and biotechnology industries, as well as with leading technology companies. His cases have involved a wide range of technologies, including gene therapy, pharmaceutical treatment methods, oncology diagnostics, DNA sequencing, antibody manufacturing, drug formulations, lipid nanoparticle delivery technology for mRNA vaccines, minimal residual disease assays, cloud computing, music streaming, and cybersecurity.

Charles was a member of the Morrison Foerster team that represented Arbutus Biopharma in its patent infringement litigation against Moderna over the lipid nanoparticle delivery technology behind Moderna's COVID-19 vaccine, Spikevax, which resulted in a $2.25 billion global settlement. He was also a member of the team that secured summary judgment in the Middle District of North Carolina on behalf of NeoGenomics, Inc. in a patent dispute with Natera, Inc. involving minimal residual disease assays.

Charles received his J.D., cum laude, from Duke University School of Law, where he served as the special projects editor for the Duke Law & Technology Review. While at Duke Law, he spent two semesters working in the Health Justice Clinic to serve the unmet legal needs of underserved members of the community facing serious illness. Charles also concurrently received an M.A. in bioethics and science policy from Duke University Graduate School. He received a B.S., summa cum laude, in biochemistry and molecular biology from Mississippi State University.